论文部分内容阅读
目的:了解大剂量的普伐他汀对血浆C反应蛋白(CRP)的影响。方法:将84例合并血脂异常的冠心病高危人群随机分为2组:治疗组有42例(口服普伐他汀20mgqn×6个月);强化治疗组有42例(口服普伐他汀40mgqn×6个月),治疗前后分别测定2组患者血浆总胆固醇TC、甘油三酯TG、高密度脂蛋白HDL-ch、低密度脂蛋白LDL-ch和血浆C反应蛋白(CRP)的浓度。结果:六个月后,治疗组患者的TC、TG、LDL-ch分别降低了20.2%,5.95,22.2%,HDL-ch升高了8.26%,CRP降低了8.1%,且独立与TC、TG、LDL-ch的降低;强化治疗组TC、TG、LDL-ch分别降低了31.4%,13.5%,31.5%HDL-ch升高了18.69%,CRP降低了34.9%。结论:普伐他汀可以在短期内对血脂异常有明显的调节作用,还可以降低血浆CRP的水平,较大剂量时此作用更加明显,且降低CRP水平的作用独立于调脂作用以外。
Objective: To investigate the effect of high-dose pravastatin on plasma C-reactive protein (CRP). Methods: Eighty-four high-risk CHD patients with dyslipidemia were randomly divided into two groups: 42 in the treatment group (pravastatin 20 mgqn × 6 months), and 42 in the intensive treatment group (pravastatin 40 mgqn × 6 Month). The levels of total cholesterol TC, triglyceride TG, high density lipoprotein HDL-ch, low density lipoprotein LDL-ch and plasma C-reactive protein (CRP) were measured in two groups before and after treatment. Results: Six months later, the TC, TG and LDL-ch in treatment group decreased by 20.2%, 5.95 and 22.2%, HDL-ch increased by 8.26% and CRP decreased by 8.1% , LDL-ch decreased. The levels of TC, TG and LDL-ch in the intensive treatment group decreased by 31.4%, 13.5% and 31.5% respectively. The HDL-ch increased by 18.69% and the CRP decreased by 34.9%. CONCLUSION: Pravastatin can significantly regulate dyslipidemia in a short period of time and also decrease plasma CRP. This effect is more pronounced at higher doses, and the effect of reducing CRP is independent of lipid-lowering effect.